Compliance Persona: Head of Pharmacovigilance Operations Autonomy: Assist · System drafts, human drives

AI Pharmacovigilance Case Intake

Pharmacovigilance case intake collects possible adverse event reports from every channel, including medical information contact centre calls, email, web forms, literature and partners. It records day zero, checks the four minimum criteria for a valid ICSR, screens for duplicates and hands a structured case to data entry. AI can triage, extract and pre-fill those steps with citations; case processors verify every field, qualified safety staff make the medical assessments, and the agent never submits ICSRs.

At a glance

Trigger: A message, document or publication that may describe a suspected adverse reaction reaches a safety intake channel. Owner: Head of Pharmacovigilance Operations. Primary output: Pre-filled case draft with source citations for every field. Consequential actions require approval.

Assess your workflow
PharmaceuticalBiotechLife Sciences

By VDF AI Editorial Team · Last reviewed 30 October 2026

The Challenge

Why Intake Volume Puts Reporting Clocks at Risk

Case volumes grow with every new market, partner and literature source, yet each report still needs careful reading, and the regulatory clock starts on the day any employee or contractor learns of a valid case.

How VDF AI Handles It

Pre-Filled Case Drafts, Human Verification

VDF AI agents triage the intake queue, extract case details with citations to the source text, mask personal data where it is not needed and hand case processors a pre-filled draft with a validity checklist to verify.

Agent Workflow

How the Agent Network Works

  1. 01

    Triage Agent

    Sorts incoming mail, scanned forms and partner files into potential adverse event reports, product complaints, medical enquiries and unrelated messages.

  2. 02

    Extraction Agent

    Pulls reporter, patient, product, reaction and timing details into structured fields and links each value to the sentence it came from.

  3. 03

    Validity Agent

    Checks the four minimum criteria for a valid case and lists missing items so a processor can request follow-up.

  4. 04

    Duplicate Agent

    Compares each new report with existing cases on patient descriptors, product, reaction and dates, and lists candidates for a person to confirm.

  5. 05

    Privacy Agent

    Detects personal identifiers and masks them in copies used for analytics, training material or literature summaries.

Data and evidence

What AI Pharmacovigilance Case Intake Needs to Operate

Each pharmacovigilance case intake source has a defined purpose, freshness expectation, quality gate, and sensitivity boundary.

Intake channels such as safety mailboxes, web forms, call notes and partner files

Purpose: Give the agents every report that could start a submission clock.

Freshness: Polled continuously so day zero is never lost to an unread inbox.

Quality: Each item keeps its receipt timestamp, channel and original attachment.

Sensitivity: Treat all items as health data and limit access to the safety team.

Literature search outputs and licensed full-text articles

Purpose: Identify publications that describe a suspected reaction to a company product.

Freshness: Run at least weekly, in line with the search strategy in your procedures.

Quality: Store the search string, database, date and article identifier with every hit.

Sensitivity: Respect publisher licence terms when storing or sharing full texts.

Existing case records exported from the safety database

Purpose: Support duplicate checks and show processors related prior reports.

Freshness: Refreshed daily from the system of record.

Quality: Case identifiers and version numbers must match the safety database exactly.

Sensitivity: Export only the fields needed for duplicate detection.

Measurement plan

How to Evaluate AI Pharmacovigilance Case Intake

Primary measure: Valid reports reaching a processor within one business day of receipt. For one month before the pilot, record receipt-to-triage time, data entry effort per case and duplicates found after entry, by intake channel.
Illustrative model Value hypothesis and full cost
Illustrative: monthly report volume × processor minutes saved per case × loaded cost, plus reduced late-submission exposure, minus validation, review, model and infrastructure costs.

Cost inputs to include

  • Computerised system validation under your quality procedures
  • Processor time spent verifying drafts
  • Model capacity for multilingual documents
  • Integration with mailboxes and safety database exports
Validation Supporting measures and review cadence

Sample drafts weekly during the pilot and monthly after go-live, and repeat validation testing after any model or prompt change.

  • Fields accepted without correction per case draft
  • Confirmed duplicates found before data entry
Decision guide

AI Pharmacovigilance Case Intake: Operating Model and Implementation

Pharmacovigilance case intake in brief

Case intake is everything between “a report arrived” and “a verified case is in the safety database”: capturing the report, deciding whether it is a valid ICSR, finding duplicates and preparing the data. It is where reporting clocks start, so the job is speed with no loss of accuracy. AI shortens the reading, sorting and typing; safety professionals keep every decision about validity, seriousness and causality.

When Pharmacovigilance Case Intake is appropriate

Intake is the part of drug safety where volume and deadlines collide. Under EMA’s GVP Module VI, a valid case needs an identifiable reporter, one identifiable patient, a suspected product and a suspected reaction. Serious cases go to EudraVigilance within 15 days and non-serious ones within 90, counted from day zero. In the US, 21 CFR 314.80 requires 15-day Alert reports for serious and unexpected experiences, review of information from any source including the scientific literature, and ten years of record retention.

The workflow suits teams with steady report volume, several intake channels and a quality system that can validate a new tool. It is a poor fit when report volume is tiny or when the expectation is that software will replace safety physicians.

When AI Pharmacovigilance Case Intake is appropriate

AI intake makes sense once most of your cost sits in reading and transcribing free text: MICC call notes, emails, scanned forms, partner line listings and articles. If most reports already arrive as structured E2B files from partners, the gain is smaller and a validated import is the better first step. Expect the largest benefit on multilingual inboxes, literature hits and follow-up reports, where a person otherwise rereads the whole case to find what changed.

Intake channels and what each one needs

ChannelTypical sourceWhat intake must captureWhere AI helps
MICC calls and chatsPatients, pharmacists, physicians asking about a productReporter contact, patient descriptor, product, event, call date and timeSpotting safety content in call notes and pre-filling a case draft
Safety email inboxHealthcare professionals, consumers, sales staffOriginal message and attachments with receipt timestampSorting adverse events from complaints and enquiries
Company website and web formsConsumers and professionals reporting directlyStructured fields plus free text, submission timestampReading the free-text box and checking the criteria
LiteratureWeekly database searches, local journalsSearch string, article identifier, awareness dateScreening abstracts and full texts for a product, patient and reaction
Partners and licenseesLine listings, E2B files, safety data exchangePartner case ID, agreement reference, receipt dateMapping partner fields and finding duplicates with your own cases
Patient support programmesNurses and coordinators in organised programmesProgramme ID and solicited flagFlagging events in programme notes for the solicited workflow

Two channel rules from EMA’s GVP Module VI matter here (verified October 2026). Reports notified through medical enquiry or product information services count as spontaneous reports, so MICC staff need adverse event training and a same-day hand-off. Companies should also screen websites and digital media under their management for possible reports, often enough that valid cases still meet the submission time frames counted from the posting date. Reports from patient support programmes are solicited, not spontaneous, and need their own route.

The four minimum criteria and day zero

Per GVP Module VI, a valid ICSR needs (verified October 2026):

  1. An identifiable reporter, with qualification and country known for at least one reporter. A report from the internet counts as identifiable if, for example, a valid email address shows a real person exists.
  2. One identifiable patient, described by at least one qualifier such as initials, age, age group, date of birth or gender.
  3. At least one suspected medicinal product.
  4. At least one suspected adverse reaction. A bare outcome, such as “the patient was hospitalised”, needs medical judgement before it counts.

Day zero is the first day anyone in the company, including medical representatives and contractors, has information meeting all four criteria, weekends and public holidays included. For literature, the clock starts on awareness of a publication that contains them. An AI checklist can show which criteria are present and quote the sentence for each, but a processor confirms validity.

Reporting clocks intake has to protect

JurisdictionReport typeDeadlineSource
EUSerious valid ICSR15 days from receiptGVP Module VI
EUNon-serious valid ICSR90 days from receiptGVP Module VI
USSerious and unexpected adverse drug experience (15-day Alert report)No later than 15 calendar days from initial receipt21 CFR 314.80
US15-day Alert follow-upWithin 15 calendar days of new information21 CFR 314.80
USOther postmarketing reportsPeriodic: quarterly for three years from approval, then annually21 CFR 314.80

All rows verified October 2026. EMA states that GVP modules affected by the newly adopted ICH E2D(R1) guideline will be revised, and Module VI Rev 2 is still the current text, so recheck these rules when the revision is published. On the format side, FDA accepted E2B(R2) through 30 September 2026; from 1 October 2026, ICSRs sent through ESG NextGen must use E2B(R3).

Where AI helps and where medical review stays

StepAI can doA qualified person decides
TriageLabel each item as possible adverse event, complaint, enquiry or otherClosing any item as not safety-relevant
TranslationTranslate alongside the original textMeaning of clinical terms in context
ExtractionPre-fill reporter, patient, product, dose, dates and event text with citationsAccepting every field
Coding supportSuggest MedDRA terms for the reported eventFinal coding
ValidityShow which minimum criteria are presentWhether the case is valid
Seriousness and expectednessHighlight hospitalisation, death or other criteria mentioned in the textSeriousness, expectedness, causality
Follow-upDraft a request listing missing informationSending it and judging the reply

Cost levers for case intake

  • Structure at source. MICC scripts and web forms that ask for the four criteria up front avoid follow-up rounds.
  • Fewer touches per case. Cited pre-filled fields mean a processor checks rather than types.
  • Duplicates before entry. A duplicate caught at intake costs a comparison; one caught after entry costs a nullification and a resubmission.
  • Route by complexity. Non-serious consumer reports with complete data take a short path; serious, pregnancy and paediatric cases go to senior staff.
  • Literature screening. Weekly searches are expected under GVP Module VI (verified October 2026), and AI screening cuts the number of full texts a person must read.
  • Track the right unit. Measure cost per valid case and late submissions together.

SaaS or on-premises case intake

QuestionSaaS intakeOn-premises or private cloud intake
Time to startFast; vendor runs the stackLonger; you run infrastructure and models
Where health data sitsVendor environment, under your contractYour environment
Control of model and prompt changesVendor release cycle, which your validation must followYour change control
Validation effortVendor package plus your intended-use testingYour full validation, with more control over scope
Best fitSmaller safety teams, few marketsStrict data residency, many partners, existing validation capability

Either way, keep the validated safety database as the system of record and treat the intake layer as a feeder that a person reviews.

Designing the operating workflow

  1. Capture. Every message and file is logged with its receipt time, because that time can become day zero.
  2. Triage. The agent labels items as potential adverse events, complaints or enquiries; a person reviews anything closed as not relevant.
  3. Extract. Case fields are pre-filled, each linked to its source sentence, with foreign-language reports translated alongside the original.
  4. Validate. The four minimum criteria are checked and gaps become follow-up requests.
  5. Check duplicates. Candidates are listed for a processor to confirm or reject, following the duplicate management addendum to GVP Module VI.
  6. Hand over. The processor enters the verified case in the safety database, and qualified staff complete the medical assessment.

Data, integration, and evidence

Intake stepAgent outputHuman decision
TriageCategory with the deciding passageClose or keep each item
ExtractionCited field valuesAccept or correct every field
ValidityMissing-criteria checklistValidity and follow-up
DuplicatesRanked candidate casesMerge, link or keep separate

For follow-up reports, a diff of the new and previous versions shows processors exactly what changed. On the submission side, the FDA electronic submissions page states that ICSRs sent through ESG NextGen must use E2B(R3) from 1 October 2026 (verified October 2026). That work stays in the safety database.

How VDF.AI supports this use case

VDF AI Agents run on-premises, in a private cloud or air-gapped, so case documents stay in your environment. Agents can combine catalog tools for OCR, translation and table extraction with PII detection and PII redaction for copies that leave the case record.

VDF holds no GxP or regulatory certification of its own. It is software that runs under your quality system, so validation, access control and SOPs remain yours. The GxP AI validation guide covers how teams scope that validation for a non-critical first workload such as intake.

More healthcare workflows are in the healthcare use cases, including literature review support, regulatory knowledge chat for pharma and coding validation.

Risk and control register

Controls Required for AI Pharmacovigilance Case Intake

A report is misrouted as a medical enquiry and its clock runs out unnoticed.

Control: Processors review every item the agent labels as not an adverse event before it is closed.

Accountable owner: Intake team lead

An extracted field misstates a dose, date or reaction term.

Control: Every field links to its source sentence, and processors confirm fields before data entry.

Accountable owner: Case processing lead

Personal data flows into analytics or prompts beyond what case processing requires.

Control: Detect and mask identifiers outside the case record, and run agents only inside your environment.

Accountable owner: Data protection officer

Where this workflow should not operate

  • It does not assess seriousness, expectedness, causality or signals.
  • It does not submit ICSRs or replace the validated safety database.
  • Handwritten or low-quality scans may need full manual transcription.
Controlled rollout

Pilot and Scale Criteria

Pilot on one market's spontaneous reports in parallel with normal processing, so every case is still entered and assessed by the existing team.

Prerequisites

  • Define intended use and validation scope under your computerised system procedures.
  • Connect one intake mailbox and a read-only export of existing cases.

Approval gates

  • The QPPV or delegate approves the intended use and the parallel-run results.
  • Quality assurance signs off validation evidence before the agent touches live intake.

Scale criteria

  • No valid report is missed or delayed by the agent across the parallel run.
  • Processors accept most extracted fields without correction.
Evidence

Authoritative Sources and Implementation References

These sources inform the governance and evaluation approach for AI Pharmacovigilance Case Intake. They do not certify a specific deployment.

  1. Guideline on good pharmacovigilance practices (GVP) Module VI: Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) — European Medicines Agency, 2017
  2. 21 CFR 314.80: Postmarketing reporting of adverse drug experiences — Legal Information Institute, Cornell Law School
  3. FDA Adverse Event Monitoring System (AEMS) Electronic Submissions — U.S. Food and Drug Administration

Written by VDF AI Editorial Team. Last reviewed 30 October 2026.

FAQ

Frequently Asked Questions

Answers for Head of Pharmacovigilance Operations evaluating this workflow's data, controls, measures, and operating boundaries.

Talk to an expert
01 What is pharmacovigilance MICC intake?

MICC intake is the handling of safety information that arrives through a medical information contact centre: calls, emails and chats from patients and healthcare professionals asking about a product. EMA's GVP Module VI treats suspected reactions notified through medical enquiry or product information services as spontaneous reports (verified October 2026), so the agent who takes the call must capture the four minimum criteria and pass the report to the safety team the same day.

02 What are the four minimum criteria for a valid ICSR?

An identifiable reporter, a single identifiable patient, at least one suspected medicinal product and at least one suspected adverse reaction. GVP Module VI adds that the reporter's qualification and country must be known and that the patient needs at least one qualifying descriptor such as initials, age, age group or gender (verified October 2026). Day zero starts when anyone in the company holds all four.

03 How can pharmacovigilance case intake be made more cost effective?

Cut the touches per case rather than the review. Capture structured fields at the source with good MICC and web form templates, let AI pre-fill and cite fields from free text, catch duplicates before data entry and reserve senior processors for serious and complex cases. Measure cost per valid case and late submissions together, so savings never come from slower clocks.

04 Should pharmacovigilance case intake run as SaaS or on-premises?

Either can be compliant. SaaS intake is quicker to start and suits companies without validation and infrastructure staff. On-premises or private cloud intake keeps health data, partner files and model traffic inside your perimeter and lets your quality system control model and prompt changes. Many teams keep the validated safety database where it is and choose the intake layer on data residency and validation effort.

05 Does a pharmacovigilance AI agent submit ICSRs to regulators?

No. Submission stays in your validated safety database and its gateway connections. The agent prepares a draft that a processor verifies before data entry. That matters more now that FDA requires E2B(R3) for postmarketing ICSRs sent through ESG NextGen from 1 October 2026 (verified October 2026), because format errors are caught at the gateway, not by the agent.

Build This Use Case with VDF AI

Start building it free in the cloud, or describe your AI Pharmacovigilance Case Intake workflow and we will help map the appropriate governed agent network for your environment.